Protocol Ledger

NCT06361888 · Phase II/III · RECRUITING

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Interventional Phase II/III clinical trial protocol NCT06361888 sponsored by Hutchmed in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-08 Enrollment: 502 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06361888
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)502 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06361888
Protocol FieldVerified Registry Value
NCT IdentifierNCT06361888
Consolidated Lead SponsorHutchmed
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment502 participants (ESTIMATED)
Registered Start Date2024-05-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06361888
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI